SNOMED International Welcomes Jordan to the Global SNOMED CT Community
London, United Kingdom, Aug. 28, 2018 (GLOBE NEWSWIRE) -- SNOMED International and Electronic Health Solutions are pleased to announce that Jordan has recently joined the organization as its thirty-fifth Member.
Electronic Health Solutions (EHS), Jordan’s representative to SNOMED International, is a nonprofit company mandated to advance the public healthcare sector and transform health care through the provision of automated solutions that enhance the quality and efficiency. Through its flagship program “Hakeem” which was launched in 2009 upon a profound vision of his Majesty King Abdullah II Bin Al Hussein, EHS is responsible for the implementation of a nationwide Electronic Health Record solution for the Ministry of Health and Royal Medical Services as well as King Hussein Cancer Center and the National’s Women’s Health Care Center.
With membership in SNOMED International, EHS has committed nationwide support for structured clinical terminology in support of Jordan’s strategic health goals. The scope of Jordan’s 2018-2022 e-Health strategy includes unifying protocols, medical procedures and terminologies within all healthcare bodies in the Kingdom, presenting a clear role for SNOMED CT as a reference terminology.
SNOMED CT is the world’s most comprehensive health terminology. Founded in 2007 by nine charter nations, SNOMED International is a not-for-profit, member-owned and driven international organization. The addition of Jordan has grown the organization’s Membership to thirty-five countries and territories across five continents. SNOMED International CEO, Don Sweete, is excited to welcome Jordan to the community of the organization’s Members. With Jordan’s Membership to SNOMED International, EHS has crossed the threshold enabling Jordan to leverage SNOMED CT for the nationwide benefit of their healthcare system.” He adds, “I applaud his Majesty King Abdullah II Bin Al Hussein for his vision for healthcare within Jordan, and welcome Jordan to our thriving and collaborative Community of Practice.”
EHS CEO, Eng. Feras Kamal stressed on the vital role played by the company in unifying medical terminology between all healthcare entities throughout Jordan as this will be of great value in big data analytics.
Kamal, also points out the importance of this collaboration as it is the first step in placing Jordan as a recognized reference for medical terminology in the Arab World.
Jordan becomes the second country in the Middle East region to join SNOMED International, laying the groundwork for increased interoperability as well as the promise of leveraging learnings amongst its regional and international counterparts.
To learn more about SNOMED International and SNOMED CT, visit www.snomed.org.
To learn more about Electronic Health Solutions visit https://ehs.com.jo.
About SNOMED International:
SNOMED International is a not-for-profit organization that owns and develops SNOMED CT, the world's most comprehensive healthcare terminology product. We play an essential role in improving the health of humankind by determining standards for a codified language that represents groups of clinical terms. This enables healthcare information to be exchanged globally for the benefit of patients and other stakeholders. We are committed to the rigorous evolution of our products and services, to deliver continuous innovation for the global healthcare community. SNOMED International is the trading name of the International Health Terminology Standards Development Organization (IHTSDO.)
About Electronic Health Solutions:
Electronic Health Solutions (EHS) was founded in early 2009 to advance the healthcare sector in Jordan. EHS is an innovative technology-driven, private, non-profit company that effectively provides automated solutions to enhance the quality and efficiency of Jordanian public healthcare services.
In collaboration with strategic healthcare and technology partners, EHS is driving the future of electronic health in Jordan. These key stakeholders (owners) include the Ministry of Health (MoH), Ministry of Information and Communication Technology (MoICT), Royal Medical Services (RMS), King Hussein Cancer Foundation (KHCF), Royal Health Awareness Society, Private Hospitals Association and King Abdulla II Fund for Development.
EHS exclusively oversees three key initiatives that utilize technology to advance the quality of healthcare services in Jordan’s public health sector. The programs operated by EHS comprise Hakeem program, the Electronic Library of Medicine-Jordan (ELM) and Hakeem Academy.
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
CP Kelco Announces Plans to Invest in Specialty Biogums Capabilities and Capacity Expansion19.11.2018 14:15 | Pressemelding
ATLANTA, Nov. 19, 2018 (GLOBE NEWSWIRE) -- In response to the strong global demand for specialty Biogums products, CP Kelco announced today its plans to invest in building capabilities and expanding production capacity. As a leading global producer and innovator of hydrocolloid solutions, CP Kelco is reinforcing its commitment to three Biogums product lines – gellan gum, specialty xanthan gum and diutan gum – through these key operational initiatives: Adding gellan gum production capabilities in the company’s Wulian, China facility to support growth in the Asia Pacific region; Expanding the overall capacity of the Wulian, China facility to support growth across all three specialty Biogums product lines; and Expanding the recently added gellan gum production capacity in the company’s Okmulgee, Oklahoma, USA facility. In addition to the planned investments in new production capabilities and capacity, CP Kelco is equally committed to ensuring its Biogums products meet the high standards o
Invivoscribe Submits the LeukoStrat CDx FLT3 Mutation Assay to Support Daiichi Sankyo Submission for Quizartinib in Japan19.11.2018 14:00 | Pressemelding
SAN DIEGO, Nov. 19, 2018 (GLOBE NEWSWIRE) -- In support of an ongoing partnership with Daiichi Sankyo, Invivoscribe is pleased to announce submission of the LeukoStrat® CDx FLT3 Mutation Assay to the PMDA (Pharmaceuticals and Medical Devices Agency) as the companion diagnostic for quizartinib, which follows Daiichi Sankyo’s PMDA application for quizartinib in Japan. Invivoscribe developed the LeukoStrat CDx FLT3 Mutation Assay in partnership with Daiichi Sankyo as the companion diagnostic that bridges to the global phase 3 QuANTUM-R clinical trial (Europe, United States, Asia excluding Japan) in patients with relapsed/refractory FLT3 ITD AML. Together, QuANTUM-R clinical trial and open-label phase 2 study of quizartinib (Japan) support the Daiichi Sankyo New Drug Application (NDA) to Japan’s MHLW/PMDA for marketing approval of quizartinib for the treatment of adult patients with relapsed/refractory FLT3 ITD acute myeloid leukemia (AML). This submission complements Invivoscribe’s prior
Minerva Neurosciences Announces Results of Dose Escalation Study Evaluating Roluperidone (MIN-101) Administered at Supra-Therapeutic Doses in Healthy Volunteers19.11.2018 14:00 | Pressemelding
Findings suggest expanded therapeutic window and significantly improved cardiovascular safety margin compared to formulation used in Phase 2b trial All doses tested up to 256 milligrams appear safe and well tolerated with no significant changes in cardiac repolarization and QTc intervals Tested formulation is used in ongoing Phase 3 trial Data to be reviewed at Minerva’s roluperidone update and key opinion leader event on Tuesday, November 20, 2018 beginning at 8:00 a.m. Eastern Time in New York WALTHAM, Mass., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the results from a prospective, double-blind, placebo-controlled, randomized single-escalating dose study in healthy subjects to evaluate the investigational drug roluperidone as monotherapy administered at nine ascending doses (16, 32, 64, 96, 128, 160, 19
Clutch Ranks SoftServe Among the Top Data Analytics Companies in Ukraine19.11.2018 13:00 | Pressemelding
AUSTIN, Texas, Nov. 19, 2018 (GLOBE NEWSWIRE) -- SoftServe, a leading digital authority and consulting company, announces it has been named a top data analytics consulting company in Ukraine for its high-quality service in technology transformation consulting by Clutch, a leading B2B research, ratings, and reviews company based in Washington D.C. SoftServe ranked ninth out of more than 140 firms in the data analytics category. Clutch determines its industry leader rankings by using a methodology that evaluates companies based on industry expertise and the ability to deliver. Additional criteria includes services offered, types of clients, case studies, brand reputation, and visibility within the target market. “As part of Clutch’s service, we provide business to business firms the opportunity to evaluate companies and their competitors so that they can find the best partner to meet their needs,” said Jackie Faselt, Business Analyst at Clutch. “SoftServe’s technical expertise and positi
GridGain Experts Showcase the Power of In-Memory Computing at Multiple Industry Events19.11.2018 09:00 | Pressemelding
FOSTER CITY, Calif., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Experts from GridGain® Systems, provider of enterprise-grade in-memory computing solutions based on Apache® Ignite™, is organizing or taking part in multiple webinars, conferences and meetups during November and December to share the latest information and developments related to in-memory computing technology and business trends. “The performance challenges facing companies as they undertake digital transformation are vast, and for many companies an in-memory computing platform is the only cost-effective, easy-to-deploy technology capable of delivering the speed and scalability necessary to overcome many of those challenges,” said Terry Erisman, vice president of marketing at GridGain Systems. “Our experts travel the world to share practical advice on how to leverage the power of in-memory computing.” Conferences AWS Re:Invent 2018 – November 26, 2018 – GridGain CTO and Co-Founder Nikita Ivanov will speak on the topic of “In-Memor
Benchmark Assays 5.90 Metres at 12.62g/t AuEq From 2015 Drill-Hole That Also Provided 385.5 AuEq From Historical Assay19.11.2018 09:00 | Pressemelding
EDMONTON, Alberta, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Benchmark Metals Inc. (the “Company” or “Benchmark”) (TSX-V: BNCH) (OTCQB: CYRTF) (WKN: A2JM2X) - is pleased to announce drill-hole assays from the infill and shoulder sampling program of historical drill-core at the Lawyers Gold & Silver Project, located in the Golden Triangle region of British Columbia, Canada. Selected results from new and combined historical intersections include 5.9m at 12.62g/t AuEq (hole CC15-15), 63.75m at 1.59g/t AuEq (hole DR15-05), and 1.68m at 10.94g/t AuEq (hole DR15-01)*. CEO John Williamson commented, “Drill-hole assay results from selected historical holes continue to indicate that much of the Gold-Silver Lawyers project contains significant mineralization at surface and at shallow depths. Results from the Cliff Creek Zone and Dukes Ridge Zone are providing high-grade intersections that are enveloped by larger bulk tonnage style intersections. We anticipate more results from 2018 infill and step-out d
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom